{
    "clinical_study": {
        "@rank": "158016", 
        "arm_group": [
            {
                "arm_group_label": "Promethazine", 
                "arm_group_type": "Active Comparator", 
                "description": "IV promethazine (25 mg)"
            }, 
            {
                "arm_group_label": "lorazepam", 
                "arm_group_type": "Active Comparator", 
                "description": "IV lorazepam (2 mg)"
            }
        ], 
        "brief_summary": {
            "textblock": "This study was a prospective, randomized, double-blind, parallel group clinical trial\n      designed to compare the efficacy of intravenous (IV) promethazine and lorazepam for the\n      treatment of peripheral vertigo in Emergency Department setting."
        }, 
        "brief_title": "Promethazine vs. Lorazepam for Treatment of Vertigo", 
        "completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "condition": "Peripheral Vertigo.", 
        "condition_browse": {
            "mesh_term": [
                "Vertigo", 
                "Dizziness"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Aged 18 years or older\n\n          -  Background history of positional vertigo\n\n        Exclusion Criteria:\n\n          -  Unable to provide informed consent\n\n          -  Pregnant or possibly pregnant\n\n          -  Known allergy to study medications\n\n          -  Use of antiemetic agents in the previous 24 hours\n\n          -  Evidence of drug-induced vertigo or orthostatic hypotension\n\n          -  Central pathologies/central origin for vertigo"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "210", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01827293", 
            "org_study_id": "SB-067"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Promethazine", 
                    "lorazepam"
                ], 
                "intervention_name": "Promethazine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Promethazine", 
                    "lorazepam"
                ], 
                "intervention_name": "Lorazepam", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Promethazine", 
                "Diphenhydramine", 
                "Lorazepam"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "June 13, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Tehran", 
                    "country": "Iran, Islamic Republic of", 
                    "state": "Nezam Abad", 
                    "zip": "17666-33815"
                }, 
                "name": "Department of Neurology, Emam Hossein Hospital"
            }
        }, 
        "location_countries": {
            "country": "Iran, Islamic Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "Promethazine vs. Lorazepam for Treatment of Vertigo in the Emergency Department: A Randomized Clinical Trial", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Iran: Ministry of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The primary efficacy outcome was the mean change in the vertigo intensity score between pre- and post-intervention at  2 hours after administration of study medications.", 
            "measure": "Mean change in vertigo intensity.", 
            "safety_issue": "No", 
            "time_frame": "At 2 hours after intervention."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01827293"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Shaheed Beheshti Medical University", 
            "investigator_full_name": "Shadi Asadollahi", 
            "investigator_title": "Research Assistant", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Secondary outcomes included, mean change in nausea VAS score, need for second dose of study medications, and the rate of drug-related adverse events for the subjects in each study group after intervention.", 
            "measure": "Efficacy and Safety outcome measures (nausea change-second dose-adverse events).", 
            "safety_issue": "Yes", 
            "time_frame": "At  2-8 hours after intervention."
        }, 
        "source": "Shahid Beheshti Medical University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Shahid Beheshti Medical University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}